OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Lenvatinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer: Treatment Optimization for Maximum Clinical Benefit
Lori J. Wirth, Cosimo Durante, Duncan J. Topliss, et al.
The Oncologist (2022) Vol. 27, Iss. 7, pp. 565-572
Open Access | Times Cited: 26
Lori J. Wirth, Cosimo Durante, Duncan J. Topliss, et al.
The Oncologist (2022) Vol. 27, Iss. 7, pp. 565-572
Open Access | Times Cited: 26
Showing 1-25 of 26 citing articles:
Thyroid Cancer
Laura Boucai, Mark Zafereo, Maria E. Cabanillas
JAMA (2024) Vol. 331, Iss. 5, pp. 425-425
Closed Access | Times Cited: 175
Laura Boucai, Mark Zafereo, Maria E. Cabanillas
JAMA (2024) Vol. 331, Iss. 5, pp. 425-425
Closed Access | Times Cited: 175
Prognostic value of neutrophil-to-lymphocyte ratio in colorectal cancer liver metastasis: A meta-analysis of results from multivariate analysis
Nanping Lin, Jingrong Li, Xiangqing Yao, et al.
International Journal of Surgery (2022) Vol. 107, pp. 106959-106959
Open Access | Times Cited: 50
Nanping Lin, Jingrong Li, Xiangqing Yao, et al.
International Journal of Surgery (2022) Vol. 107, pp. 106959-106959
Open Access | Times Cited: 50
Anlotinib in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Randomized, Double-Blind, Multicenter Phase II Trial
Yihebali Chi, Xiangqian Zheng, Yuan Zhang, et al.
Clinical Cancer Research (2023) Vol. 29, Iss. 20, pp. 4047-4056
Open Access | Times Cited: 19
Yihebali Chi, Xiangqian Zheng, Yuan Zhang, et al.
Clinical Cancer Research (2023) Vol. 29, Iss. 20, pp. 4047-4056
Open Access | Times Cited: 19
Current Advances in Radioactive Iodine-Refractory Differentiated Thyroid Cancer
Fabio Volpe, Carmela Nappi, Emilia Zampella, et al.
Current Oncology (2024) Vol. 31, Iss. 7, pp. 3870-3884
Open Access | Times Cited: 7
Fabio Volpe, Carmela Nappi, Emilia Zampella, et al.
Current Oncology (2024) Vol. 31, Iss. 7, pp. 3870-3884
Open Access | Times Cited: 7
Improving the response to lenvatinib in partial responders using a Constrained-Disorder-Principle-based second-generation artificial intelligence-therapeutic regimen: a proof-of-concept open-labeled clinical trial
Tal Sigawi, Ram Gelman, Ofra Maimon, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 7
Tal Sigawi, Ram Gelman, Ofra Maimon, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 7
Genetic landscape of 482 thyroid carcinomas: analysis with the national datacenter for cancer genomic medicine in Japan
Haruhiko Yamazaki, Chikara Kunisaki, Makoto Sugimori, et al.
Endocrine (2024) Vol. 85, Iss. 2, pp. 766-776
Closed Access | Times Cited: 6
Haruhiko Yamazaki, Chikara Kunisaki, Makoto Sugimori, et al.
Endocrine (2024) Vol. 85, Iss. 2, pp. 766-776
Closed Access | Times Cited: 6
Aggressive variants of follicular cell-derived thyroid carcinoma: an overview
Cristina Pizzimenti, Vincenzo Fiorentino, Antonio Ieni, et al.
Endocrine (2022) Vol. 78, Iss. 1, pp. 1-12
Closed Access | Times Cited: 26
Cristina Pizzimenti, Vincenzo Fiorentino, Antonio Ieni, et al.
Endocrine (2022) Vol. 78, Iss. 1, pp. 1-12
Closed Access | Times Cited: 26
Lenvatinib resistance mechanism and potential ways to conquer
Wentao Bo, Yan Chen
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 15
Wentao Bo, Yan Chen
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 15
Causal relationship between gut microbiota and differentiated thyroid cancer: a two-sample Mendelian randomization study
Shaojun Hu, Chuangang Tang, Ling Wang, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 4
Shaojun Hu, Chuangang Tang, Ling Wang, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 4
Low‐Dose Versus High‐Dose Lenvatinib in Radioiodine Refractory Differentiated Thyroid Cancer—A Real‐World Safety and Efficacy Analysis
Jeepalem Sai Moulika, Kunal Ramesh Chandekar, Shubha Gadde Ravindra, et al.
Clinical Endocrinology (2025)
Open Access
Jeepalem Sai Moulika, Kunal Ramesh Chandekar, Shubha Gadde Ravindra, et al.
Clinical Endocrinology (2025)
Open Access
Targeting STARD4/EGFR axis inhibits growth and overcomes lenvatinib resistance in hepatocellular carcinoma
Mengting Liu, Yixin Liu, Jiahui Zheng, et al.
Genes & Diseases (2025), pp. 101556-101556
Open Access
Mengting Liu, Yixin Liu, Jiahui Zheng, et al.
Genes & Diseases (2025), pp. 101556-101556
Open Access
Investigation into the Use of Surufatinib and Donafenib as Novel Multi-Kinase Inhibitors Therapeutic Agents in Managing Advanced Differentiated Thyroid Cancer: A Systematic Review
Dănuț Dejeu, Paula Dejeu, Anita Muresan, et al.
Biomedicines (2025) Vol. 13, Iss. 3, pp. 752-752
Open Access
Dănuț Dejeu, Paula Dejeu, Anita Muresan, et al.
Biomedicines (2025) Vol. 13, Iss. 3, pp. 752-752
Open Access
Advances in Diagnosis and Treatment of Radioactive Iodine Refractory Differentiated Thyroid Cancer
Yongji Jiang, Chao Ma, Renfei Wang, et al.
IntechOpen eBooks (2025)
Closed Access
Yongji Jiang, Chao Ma, Renfei Wang, et al.
IntechOpen eBooks (2025)
Closed Access
Neoadjuvant therapy to improve resectability of advanced thyroid cancer: A real‐world experience
Marika D. Russell, Matti L. Gild, Lori J. Wirth, et al.
Head & Neck (2024) Vol. 46, Iss. 10, pp. 2496-2507
Closed Access | Times Cited: 3
Marika D. Russell, Matti L. Gild, Lori J. Wirth, et al.
Head & Neck (2024) Vol. 46, Iss. 10, pp. 2496-2507
Closed Access | Times Cited: 3
Management of Progressive Radioiodine-Refractory Thyroid Carcinoma: Current Perspective
Alice Nervo, Francesca Retta, Alberto Ragni, et al.
Cancer Management and Research (2022) Vol. Volume 14, pp. 3047-3062
Open Access | Times Cited: 12
Alice Nervo, Francesca Retta, Alberto Ragni, et al.
Cancer Management and Research (2022) Vol. Volume 14, pp. 3047-3062
Open Access | Times Cited: 12
Development of TSHR-CAR NK-92 Cells for Differentiated Thyroid Cancer
Jiahui Zhou, Chengcheng Zhang, Weibo Mao, et al.
Molecular and Cellular Endocrinology (2024) Vol. 589, pp. 112251-112251
Closed Access | Times Cited: 2
Jiahui Zhou, Chengcheng Zhang, Weibo Mao, et al.
Molecular and Cellular Endocrinology (2024) Vol. 589, pp. 112251-112251
Closed Access | Times Cited: 2
Tyrosine Kinase Inhibitors for Radioactive Iodine Refractory Differentiated Thyroid Cancer
Christos Cortas, Haris Charalambous
Life (2023) Vol. 14, Iss. 1, pp. 22-22
Open Access | Times Cited: 6
Christos Cortas, Haris Charalambous
Life (2023) Vol. 14, Iss. 1, pp. 22-22
Open Access | Times Cited: 6
Outcome of initial lenvatinib treatment in patients with unresectable anaplastic thyroid cancer
Hiroyuki Iwasaki, Soji Toda, Akari Takahashi, et al.
Oncology Letters (2023) Vol. 26, Iss. 3
Open Access | Times Cited: 5
Hiroyuki Iwasaki, Soji Toda, Akari Takahashi, et al.
Oncology Letters (2023) Vol. 26, Iss. 3
Open Access | Times Cited: 5
Clinicopathological features of differentiated thyroid carcinoma as predictors of the effects of radioactive iodine therapy
Wen Liu, Beibei Jiang, Jingli Xue, et al.
Annals of Diagnostic Pathology (2023) Vol. 69, pp. 152243-152243
Closed Access | Times Cited: 4
Wen Liu, Beibei Jiang, Jingli Xue, et al.
Annals of Diagnostic Pathology (2023) Vol. 69, pp. 152243-152243
Closed Access | Times Cited: 4
Current Advances in Radioactive Iodine Refractory Differentiated Thyroid Cancer
Fabio Volpe, Carmela Nappi, Emilia Zampella, et al.
(2024)
Open Access | Times Cited: 1
Fabio Volpe, Carmela Nappi, Emilia Zampella, et al.
(2024)
Open Access | Times Cited: 1
Schilddrüsenkarzinome – Rolle internistischer Systemtherapien
Tim Brandenburg, Matthias Kroiß
Deleted Journal (2024) Vol. 65, Iss. 7, pp. 642-655
Closed Access | Times Cited: 1
Tim Brandenburg, Matthias Kroiß
Deleted Journal (2024) Vol. 65, Iss. 7, pp. 642-655
Closed Access | Times Cited: 1
Metabolomics reveals the implication of acetoacetate and ketogenic diet therapy in radioiodine-refractory differentiated thyroid carcinoma
Jiaqi Wang, Qian-Qian Xu, Ziyang Xuan, et al.
The Oncologist (2024) Vol. 29, Iss. 9, pp. e1120-e1131
Open Access | Times Cited: 1
Jiaqi Wang, Qian-Qian Xu, Ziyang Xuan, et al.
The Oncologist (2024) Vol. 29, Iss. 9, pp. e1120-e1131
Open Access | Times Cited: 1
Clinical Effect Observation of Apatinib Combined with 131I for Radioiodine-Refractory Differentiated Thyroid Cancer and Prognostic Significance Analysis of Macrophage Inflammatory Protein-1α After Treatment: A Cell Regulation Study
Junru Liu, Meng Li, Weiying Zheng, et al.
International Journal of Morphology (2024) Vol. 42, Iss. 2, pp. 409-415
Open Access
Junru Liu, Meng Li, Weiying Zheng, et al.
International Journal of Morphology (2024) Vol. 42, Iss. 2, pp. 409-415
Open Access
The potential of lenvatinib in breast cancer therapy
Yuefeng Shang, Ying Liu, Wenjing Wang
Medical Oncology (2024) Vol. 41, Iss. 9
Closed Access
Yuefeng Shang, Ying Liu, Wenjing Wang
Medical Oncology (2024) Vol. 41, Iss. 9
Closed Access
A Summary of State-of-the-Art Clinical Trials for Advanced Thyroid Cancers, Organized by the International Thyroid Oncology Group
Laura Boucai, Ashish V. Chintakuntlawar, David C. Shonka
Clinical Thyroidology (2023) Vol. 35, Iss. 9, pp. 350-354
Closed Access
Laura Boucai, Ashish V. Chintakuntlawar, David C. Shonka
Clinical Thyroidology (2023) Vol. 35, Iss. 9, pp. 350-354
Closed Access
